Tag Archives: (GILD)

From 365 to 2

Did you know that back in 1928, Alexander Fleming discovered penicillin purely by accident when he forgot to clean up his lab before going on vacation? Sometimes the most revolutionary medical breakthroughs happen when you least expect them. Fast forward to today, and Gilead Sciences (GILD) just pulled off something that might not be accidental, […]

The British Are Coming Back

In a market where biotech usually gets lumped into either “future cure” or “eternal underdog,” GSK (GSK) is carving out a third category: cash-flowing, specialty-driven, and still misunderstood. It’s not the hottest name in oncology. It’s not a dividend aristocrat either. But if you’re looking for where the next rerating in big pharma might come […]

The Biotech That Figured Out How To Make Oxygen Profitable

A few months ago, I was catching up with a former colleague over coffee when he casually mentioned something that nearly made me spit out my latte. “You know this little pill I take twice a day?” he said, tapping his chest. “It probably costs more than most people’s rent. Maybe their mortgage too.” He […]

Biotech’s Awkward Middle Child

Well, folks, I’ve been trading biotech stocks since before most of today’s analysts had their first internships. After countless dinners with pharma execs and more investor conferences than I care to remember, there’s one thing I’ve learned about this sector – these stocks are a lot like the experimental drugs themselves: sometimes miraculous, sometimes disappointing, […]